rgp120/hiv-1mn
Vaccineexperimental
Clinical trial activity
13 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00001052)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virus type I enhancer-binding protein 1Immunity, active
HIVEP1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rgp120/hiv-1mn
- rgp120/hiv-1mn monovalent octameric v3 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00007332 | Phase 2 | Dec 16, 2000 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000775 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000853 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000879 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT00001031 | Phase 2 | Nov 2, 1999 | Chiron, Genentech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001041 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001044 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001052 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001096 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002428 | Phase 1 | Nov 2, 1999 | United Biomedical |
| NCT00002441 | Phase 3 | Nov 2, 1999 | VaxGen |
| NCT00000755 | Phase 1 | Nov 2, 1999 | Genentech, Glaxo Wellcome, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000774 | Phase 1 | — | Chiron, Genentech, National Institute of Allergy and Infectious Diseases (NIAID), New York University |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 11 | 11 | 2 | 1999 |
| Genentech | For profit | 3 | 0 | 2 | 1999 |
| Chiron | For profit | 2 | 0 | 2 | 1999 |
| Glaxo Wellcome | For profit | 1 | 0 | 1 | 1999 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 1999 |
| New York University | Academic/Hospital | 1 | 0 | 1 | — |
| United Biomedical | For profit | 1 | 1 | 1 | 1999 |
| VaxGen | For profit | 1 | 1 | 1 | 1999 |
8 organizations
Page 1 / 1